Cocrystal Pharma (COCP) News Today $1.58 -0.01 (-0.32%) As of 05/2/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 VariantsApril 24, 2025 | finanznachrichten.deCocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 VariantsApril 24, 2025 | globenewswire.comCocrystal Pharma Presents to Investment CommunityApril 23, 2025 | tipranks.comCocrystal Pharma to Present at Life Science Innovation Northwest 2025 ConferenceApril 16, 2025 | globenewswire.comOTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst ...April 10, 2025 | msn.comCocrystal Pharma Approves 2025 Equity Incentive PlanApril 8, 2025 | tipranks.comCOCP: Norovirus Challenge Study Planned for 2025…April 2, 2025 | finance.yahoo.comCocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 31, 2025 | globenewswire.comCocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025March 6, 2025 | globenewswire.comCocrystal Pharma And 2 Other Promising US Penny Stocks To WatchFebruary 12, 2025 | finance.yahoo.comCocrystal Pharma, Inc. (COCP)January 14, 2025 | finance.yahoo.comCOCP: Phase 2a Trial of CC-42344 Extended…January 9, 2025 | finance.yahoo.comDow Dips Over 100 Points; Cocrystal Pharma Shares SlideDecember 31, 2024 | benzinga.comCocrystal Pharma Shares Fall After Flu-Treatment Study Is ExtendedDecember 31, 2024 | marketwatch.comCocrystal stock plunges 40% on influenza drug updateDecember 31, 2024 | seekingalpha.comCocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344December 31, 2024 | globenewswire.comCOCP stock touches 52-week high at $3.1 amid market optimismDecember 29, 2024 | investing.comCOCP: Multiple Upcoming Catalysts…November 19, 2024 | msn.comNovember 2024 US Exchange Standouts: Promising Penny StocksNovember 16, 2024 | nz.finance.yahoo.comCocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNovember 13, 2024 | finance.yahoo.comHere's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn SituationOctober 18, 2024 | finance.yahoo.comCocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose CohortsSeptember 26, 2024 | finance.yahoo.comBuy Rating Affirmed for Cocrystal Pharma Amid Promising Drug Pipeline and Strong Clinical ResultsAugust 22, 2024 | markets.businessinsider.comCOCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…August 19, 2024 | msn.comCocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment ConferencesAugust 19, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and IGM Biosciences (IGMS)August 15, 2024 | markets.businessinsider.comCocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsAugust 14, 2024 | stockhouse.comCocrystal Pharma Gets Positive Result From Phase 1 Study With CDI-988; Stock UpJuly 19, 2024 | markets.businessinsider.comCOCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…July 19, 2024 | msn.comCOCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344…May 16, 2024 | finance.yahoo.comCOCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024May 13, 2024 | investorplace.comCocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMay 13, 2024 | globenewswire.comEnrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaMay 1, 2024 | finance.yahoo.comEnrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaMay 1, 2024 | globenewswire.comCOCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…April 23, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)April 5, 2024 | markets.businessinsider.comCOCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023March 28, 2024 | msn.comCocrystal Pharma, Inc.: Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 28, 2024 | finanznachrichten.deRecap: Cocrystal Pharma Q4 EarningsMarch 28, 2024 | benzinga.comCocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 28, 2024 | globenewswire.comCocrystal Pharma, Inc.: Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AMarch 20, 2024 | finanznachrichten.deCocrystal Pharma Receives Pre-IND Feedback Regarding CC-42344 - Quick FactsMarch 19, 2024 | markets.businessinsider.comCocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AMarch 19, 2024 | globenewswire.comCocrystal Pharma Inc (COCP)February 24, 2024 | investing.comCOCP: Cocrystal Pharma provides updates on its clinical programs.February 20, 2024 | finance.yahoo.comCocrystal Pharma Inc COCPFebruary 11, 2024 | morningstar.comCocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesJanuary 4, 2024 | finance.yahoo.comCocrystal Pharma Stock (NASDAQ:COCP), Analyst Ratings, Price Targets, PredictionsDecember 26, 2023 | benzinga.comCocrystal Pharma Stock (NASDAQ:COCP) Dividends: History, Yield and DatesDecember 26, 2023 | benzinga.comCocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ADecember 6, 2023 | finance.yahoo.com Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Email Address COCP Media Mentions By Week COCP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COCP News Sentiment▼0.000.73▲Average Medical News Sentiment COCP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COCP Articles This Week▼00▲COCP Articles Average Week Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IZTC News Today CABA News Today VTGN News Today IMAB News Today ANRO News Today PYRGF News Today CLSD News Today PYXS News Today BYSI News Today RANI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COCP) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.